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Abstract: Our previous analysis using genome-wide microarray expression data revealed 
extreme overrepresentation of immune related genes belonging the Natural Killer (NK) 
Cell Mediated Cytotoxicity pathway (hsa04650) in human abdominal aortic aneurysm 
(AAA). We followed up the microarray studies by immunohistochemical analyses using 
antibodies against nine members of the NK pathway (VAV1, VAV3, PLCG1, PLCG2, 
HCST, TYROBP, PTK2B, TNFA, and GZMB) and aortic tissue samples from AAA repair 
operations (n = 6) and control aortae (n = 8) from age-, sex- and ethnicity-matched donors 
from autopsies. The results confirmed the microarray results. Two different members of 
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the NK pathway, HCST and GRZB, which act at different steps in the NK-pathway, were 
actively transcribed and translated into proteins in the same cells in the AAA tissue 
demonstrated by double staining. Furthermore, double staining with antibodies against 
CD68 or CD8 together with HCST, TYROBP, PTK2B or PLCG2 revealed that CD68 and 
CD8 positive cells expressed proteins of the NK-pathway but were not the only 
inflammatory cells involved in the NK-pathway in the AAA tissue. The results provide 
strong evidence that the NK Cell Mediated Cytotoxicity Pathway is activated in human 
AAA and valuable insight for future studies to dissect the pathogenesis of human AAA. 
Keywords: human aorta; immunohistochemistry; double-staining; AAA; aortic aneurysm 
 
1. Introduction 
Abdominal aortic aneurysm (AAA) is a complex disease of the aging population that is associated 
with significant morbidity and mortality [1–3]. Aneurysms form through a complex remodeling  
process of the vessel wall involving inflammatory infiltration, degradation of extracellular matrix 
(ECM) and the loss of smooth muscle cells (SMC), all of which contribute to weakening and dilatation of 
the aorta [4]. Since the initial characterization of lymphocytes and macrophages in excised AAA  
tissue [5–7] infiltrating immune cells have been increasingly recognized as critical mediators in the 
pathogenesis of AAA through a variety of functions including release of proinflammatory cytokines, 
secretion of ECM degrading proteases, and production of reactive oxygen species [3,4,8]. 
Whole genome expression profiling is an unbiased method to identify the molecular pathways  
active in AAA tissue by providing a global snapshot of differentially expressed genes [9]. In the only 
whole genome microarray study comparing AAA tissue with age-matched controls, Lenk et al. found  
a significant upregulation of genes and pathways related to immune response and inflammation [10], 
including genes previously identified in AAA tissue such as MMP9, IL1 and CTSH. Based upon 
pathway analysis using functional annotation from the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) [11], the most significantly upregulated set of genes was the KEGG pathway “Natural Killer 
(NK) Cell Mediated Cytotoxicity” (Figure 1). Each KEGG pathway is a collection of genes with  
well-described interactions; the genes in the “NK Cell Mediated Cytotoxicity” pathway collectively 
form a set of signaling pathways well-described in the activation, inhibition and down-stream actions 
of NK cells. The activation of the NK pathway is initiated by contact of the NK cell with a target cell 
(e.g., tumor cells, infected cells and others) [12,13]. Involved in the activation are more than  
100 different genes whose products are localized on the cell surface, in the cytoplasm and nucleus 
(Figure 1). The final product of the cascade tumor necrosis factor (TNF) is released and additionally 
granzyme (GRZMB) and perforin (PRF1) are synthesized in cytotoxic granules and secreted by 
exocytosis to destroy the target cell directly (Figure 1) [12]. 
This study aimed to validate the protein expression of the NK cytotoxic signaling pathway 
identified by Lenk et al. [10] in AAA tissue. To accomplish this, we selected nine members, 
representing different stages of the activation, of the NK Cell Mediated Cytotoxicity Pathway and 
carried out histological analysis using tissues samples collected from AAA repair operations and 
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infrarenal aortic samples from age-, sex- and ethnicity-matched controls. As NK cells are present in 
only low numbers in AAA based on previous studies [14,15], the cellular expression of these proteins 
in other inflammatory cells was characterized using markers for lymphatic cells (CD8+) and 
monocytes/macrophages (CD68+). 
 
Figure 1. Modified “Natural Killer Cell Mediated Cytotoxicity” (hsa04650) pathway from 
Kyoto Encyclopedia of Genes and Genomes (KEGG). Protein symbols were replaced by 
gene symbols. Proteins investigated in the current study using immunohistochemical 
analysis of human aortic tissue samples from abdominal aortic aneurysm (AAA) and  
non-AAA samples are shown in bright colors. See key for explanation of colors and 
symbols. The figure is modified from our previous study [10]. 
2. Results 
2.1. Immunohistochemical Analysis Demonstrates Staining of Members of NK Cell Mediated 
Cytotoxicity Pathway in Human AAA Tissue 
We studied the protein expression of nine different members of the NK Cell Mediated Cytotoxicity 
Pathway (VAV1, VAV3, PLCG1, PLCG2, HCST, TYROBP, PTK2B, TNFA, and GZMB; Figure 1)  
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in human AAA and compared the results to aortic tissue samples taken from the infrarenal aortae of  
age- and sex-matched controls (Table 1). Eight (VAV1, VAV3, PLCG2, HCST, TYROBP, PTK2B, 
TNFA, and GZMB) of the corresponding mRNAs of these proteins had been shown to be significantly 
elevated and one (PLCG1) significantly decreased in AAA compared to non-aneurysmal aortae (Figure 1). 
Table 1. Aortic tissue samples used for immunohistochemical staining. 
Case ID Age (Years) Sex Cause of Death Classification 
ME0101 53 Male Gunshot Wound Control 
ME0105 53 Male Unknown Control 
ME0205 78 Male Cardiac Arrest Control 
ME0501 69 Female Fall (Head Trauma) Control 
ME0503 54 Male Cardiac Arrest Control 
ME0505 59 Female Cardiovascular Control 
ME1001 88 Female Trauma Control 
ME1003 44 Male Overdose/Cardiovascular Control 
WSU052 70 Male NA AAA 
WSU060 70 Male NA AAA 
WSU068 72 Male NA AAA 
WSU075 67 Male NA AAA 
WSU080 64 Female NA AAA 
WSU081 69 Male NA AAA 
Tissue samples were obtained at autopsy or at operation, and were taken from the infrarenal abdominal aorta. 
All individuals were Caucasian. Tissue samples from WSU080 were used for both microarray expression 
study [10] and the current immunostaining study. The same autopsy samples have been used in our previous 
studies and have shown comparable performance in mRNA and protein analyses to samples taken from AAA 
operations [16–20]. NA, not applicable, since the sample was obtained during an AAA repair operation. 
Immunohistochemical results with representative images of the single staining are summarized in 
Figure 2. The antibody against VAV1 showed strong staining in AAA tissue, but no staining in control 
aorta. The staining was cytoplasmic and seen mainly in inflammatory cells in all layers of AAA wall. 
The positively stained inflammatory cells were likely granulocytes based on their large size and the 
lobed nuclei. Similarly, the antibody against VAV3 stained inflammatory cells in the adventitia, media 
and intima in AAA tissues, but gave no staining in the control aorta. 
Consistent with mRNA studies (Figure 1), AAA tissue showed no staining against PLCG1 
antibody, while control tissue had ubiquitous staining in endothelial cells of the vasa vasorum and in 
the vascular smooth muscle cells (VSMCs) (Figure 2). The other subunit of the phospholipase C, 
gamma protein, PLCG2, showed stronger staining in AAA than in control aortae. Inflammatory cells 
including lymphocytes and granulocytes (based on nuclear morphology) were PLCG2-positive. 
Additionally, in the AAA tissue, endothelial cells in the vasa vasorum of the adventitia, neovessels in 
the media and adipocytes in the adventitia showed strong staining for PLCG2. 
  




Figure 2. Immunohistochemical staining with antibodies against nine different proteins 
representing the NK pathway. Each row shows representative immunohistological images 
for the indicated antibodies on AAA tissue and control abdominal aortic tissue. Most 
antibodies demonstrated staining on inflammatory cells in the AAA tissue. See Tables 1 and 2 
for details on the aortic tissues and antibodies used, respectively. Scale bar = 50 μm. 
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Inflammatory cells (granulocytes and some lymphocytes) in AAA samples were also positive for 
HCST (DAP10) with no staining in control aortae (Figure 2). Antibody against TYROBP (DAP12) 
showed intense cytoplasmic and nuclear staining of inflammatory cells (lymphocytes and granulocytes)  
in adventitia and media of AAA tissue. Similarly, inflammatory cells (lymphocytes and granulocytes) 
had a strong staining against PTK2B (PYK2) in AAA tissue. Additionally, VSMCs showed 
cytoplasmic staining for PTK2B in AAA, but there was no staining in the control aortae (Figure 2). 
The antibody against TNFA showed staining in AAA tissue mainly in adventitia and media (Figure 2). 
Inflammatory cells as well as endothelial cells of the vasa vasorum and the neovessels and VSMCs  
in the media were positive for TNFA. In control aortae, the few visible inflammatory cells and VSMCs 
showed a positive staining for TNFA. Staining for GZMB was present in inflammatory cells in all 
layers of AAA tissue, but control aortae were negative (Figure 2). 
2.2. Immunohistochemical Analyses with Double Staining Show Co-Localization of Proteins 
Participating in the Early and Late Steps of the NK Pathway Activation 
Immunohistochemical results with representative images of the double staining are shown in  
Figures 3 and 4. We first used double-staining to study the co-expression of two different members of 
the NK pathway. These studies revealed that inflammatory cells in AAA wall were positive for both 
HCST (DAP10) and GRZB (Figure 3 and Supplementary Figure S1). These findings indicated that 
HCST (DAP10) and GZMB, both of which are enzymes and act at different steps in the NK-pathway, 
were actively transcribed and translated into proteins in the same cells in the AAA tissue (Figure 3 and 
Supplementary Figure S1). 
We also used two cell-specific markers, CD68 for macrophages/monocytes and CD8 for lymphocytes, 
to carry out double-staining experiments together with members of the NK pathway. Many 
inflammatory cells, mainly in the adventitia and media in the AAA wall stained positive for PLCG2, 
but only a few of those cells expressed CD8 (Figure 4 and Supplementary Figure S2). While nearly half of 
the inflammatory cells were CD8-positive lymphocytes, only a few of them also expressed TYROBP 
(Figure 4 and Supplementary Figure S2). CD8-positive leukocytes stained with antibody against 
PTK2B. There were, however, also CD8-negative cells which showed staining for PTK2B. This 
finding suggests that different cell types express PTK2B (Figure 4 and Supplementary Figure S2). 
 
Figure 3. Cont. 




Figure 3. Double-staining with antibodies against HCST (red) and GMZB (brown) in 
AAA tissue. The donors were WSU060 (A); and WSU052 (B) for the AAA tissues used in 
the staining shown in the upper and lower panels, respectively. See Tables 1 and 2 for 
details on the aortic tissues and antibodies used, respectively, and Supplementary Figure S1 
for additional images. Scale bar = 50 µm. 
Double staining was seen with anti-CD68 and anti-TYROBP indicating that macrophages express 
TYROBP (Figure 4 and Supplementary Figure S3). CD68-positive macrophages also showed cytoplasmic 
staining against anti-PLCG2. The double staining showed that PLCG2 had ubiquitous expression  
and staining for anti-PLCG2 was also seen in other inflammatory and epithelial cells (Figure 4 and 
Supplementary Figure S3). Macrophages (CD68-positive cells) were also PTK2B-positive (Figure 4 
and Supplementary Figure S3), a finding consistent with previous studies showing expression of this 
gene in macrophages and demonstrating that it is required for macrophage migration and function [21,22]. 
 
Figure 4. Double-staining with different combinations of antibodies in AAA tissue. CD68 
staining identifies monocytes and macrophages, and CD8 identifies cytotoxic T-cells.  
For the CD8–PLCG2 double-staining (upper left image), brown color is for PLCG2 and 
red for CD8. For all other images, brown color is for CD8 or CD68 and red color is for 
PLCG2, TYROBP, or PTK2B. See Tables 1 and 2 for details on the aortic tissues and 
antibodies used, respectively, and Supplementary Figures S2 and S3 for additional images. 
The slides were counterstained with hematoxylin, and nuclei stain blue-purple color. 
Lymphocytes show intense blue staining, since they have little cytoplasm. Scale bar = 50 µm. 




Based on histopathological examination, the wall of AAA exhibits features of chronic inflammatory 
disease and vascular inflammation [23]. In a recent review Libby and Hansson [24] emphasized the 
role inflammation and the immune system play in many arterial diseases including AAAs. They called 
it the “immunopathogenesis of arterial diseases” and urged to “think beyond the intima and include the 
other layers of the artery wall”. Previous studies have suggested that the innate immune system, such 
as the complement cascade [16], and the adaptive immune system play roles in AAA, and infiltrating 
leukocytes are present in AAA [23,25]. Several previous studies provided evidence that NK cytotoxic 
pathway contributes to AAA pathobiology even in the macroscopically non-inflammatory AAAs. 
These included studies that demonstrated the presence of NK cells and NKT cells in the aneurysmal 
wall [25], found large numbers of NK cells in the peripheral blood of AAA patients [23], and 
discovered increased mRNA expression of natural killer cell associated protein (NKTR) in the aortic 
neck [26]. The NK cells from patients with AAA were also shown to have increased cytotoxicity [23]. 
Additionally the higher percentage of NK cells and the higher cytotoxicity was persistent after AAA 
repair [23], which could be a sign of systemic disease. Furthermore, one study showed that AAA 
patients have increased serum levels of TNFA [27] and another study showed that T cells isolated from 
AAA patients secreted more TNFA in vitro [15]. All of these studies provided evidence for the NK 
pathway activation in AAA. 
Previous results from a microarray-based mRNA expression study comparing AAA and  
non-aneurysmal infrarenal aortic tissue showed an increase in 43 of 49 differentially expressed genes 
from the NK pathway [10]. Similarly, prior work using the apolipoprotein E deficient mouse model of 
aortic aneurysms found an activation of the same pathway in the aortas of animals treated with 
angiotensin II as compared with controls [28]. Nine (HCST, TYROBP, PTK2B, VAV1, RAC2, FCGR3, 
FCER1G, LCP2, and CD48) of the 10 genes described as up-regulated in the mouse study were also  
up-regulated in our study of human AAA tissue [28]. The animal study did not, however, show an 
increase of the final products TNF and GZMB in the aneurysm group [28]. This is somewhat surprising 
since the complete activation of the NK pathway would require these gene products and they were 
clearly elevated in human AAA based on the current and previous studies [29]. TNFA functions in cell 
apoptosis and induces MMP expression [27]; GZMB can lyse target cells [12,30]. Perforin is also 
known to be expressed in NK cells and cytotoxic T-cells in human AAA [15,31]. 
In the current study, the immunostaining of selected members in the NK-pathway confirmed the 
mRNA expression results on the protein level (Figure 2). The histological investigation suggested NK 
cells were not the only cell type involved in the activation of the NK pathway because most 
inflammatory cells showed positive staining (Figure 2). A double staining with GZMB and HCST 
demonstrated that products of the beginning of the activation pathway and the final products were 
produced in the same cell, providing evidence for the complete activation of the pathway (Figure 3 and 
Supplementary Figure S1). 
As the number of NK cells is reported to be small in AAA [14,15], it was of interest to see which 
other cell types have an activated NK pathway. The inflammation in the AAA wall is characterized 
mainly by CD3+ T cells and B cells, a few macrophages and NK cells [14,32]. Macrophages (CD68+) 
and cytotoxic T cells (CD8+) are thought to play an important role in AAA development by expressing 
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perforin (PRF1) which can damage the membrane of the target cell [15]. The mRNA for PRF1 was 
detectable only in AAA tissue, not in the non-aneurysmal aorta. Abundant GZMB expression in 
human AAA tissue by immunostaining was demonstrated in a previously published study [30]. In the 
apolipoprotein E mouse model, GZMB was shown to act independently of perforin in AAA and 
absence of GZMB decreased the rate of AAA formation [30]. These results were consistent with the 
microarray-based expression study [10]. 
TNFA is one of the best studied cytokines in AAA, and has been shown consistently to be 
upregulated in AAA [29]. Increased levels of TNFA in serum and aorta have been described in human 
AAA [29,33]. In a CaCl2-induced AAA mouse model, blockage of TNFA attenuated aneurysm 
formation [34]. In another study using cultured murine SMCs, TNF activated Mmp9 and Timp1 which 
are known to play important roles in the remodeling of the ECM [35]. The increased expression of 
TNFA in the RNA microarray study [10] and the increased protein levels found in the current 
immunostaining study add further evidence that TNFA is important in AAA pathogenesis. 
Other components of the NK pathway such as VAV1, VAV3, PLCG1, PLCG2, HCST, TYROBP, 
and PTK2B have not been investigated in AAA previously. These proteins were investigated in  
several studies focusing on other vascular conditions including atherosclerosis, platelet activation and 
hyperlipidemia as well as activation of macrophages [36–41]: VAV proteins play an important role in foam 
cell (which are lipid-laden macrophages and the earliest form of atherosclerotic lesions) formation [39]. 
Another study showed that VAV1 and VAV3 play a role in increased platelet reactivity associated 
with hyperlipidemia [36]. Thus, it is possible that the increased expression of VAV3 in AAA tissue is 
due to intraluminal thrombus formation commonly seen in AAA. Interestingly, a mutation in the 
PLCG2 gene led to increased activity of PLCG2 and a severe autoimmune disease [41]. Since AAA is 
also an autoimmune disease, one could speculate that the increased levels of PLCG2 seen in the 
current study contribute to AAA pathophysiology. TYROBP (DAP12) has also been studied in 
metabolic, cardiovascular and inflammatory diseases [38]. 
PLCG1 is necessary for the activation of VAV1 in macrophages and is a protein which plays  
a critical role in intracellular calcium signaling [39]. The calcium signaling pathway was also 
identified among enriched pathways in a recent microarray-based study on human AAA [17]. PTK2B 
(PYK2) is activated in regulation of mononuclear phagocytosis to atherosclerotic lesions [37]. A role 
for HCST (DAP10) in aneurysm or atherosclerosis has not been described previously, but the 
NKD2D/DAP10 receptor complex is known to play a crucial role in macrophage activation [40] 
further supporting the results of macrophage activation seen in the AAA tissue. 
The results of the double immunostaining revealed the complexity of the inflammatory cells in the 
AAA wall. The expression of the components of the NK pathway is not restricted to one cell type. 
Double staining with antibodies against macrophages/monocytes (CD68) combined with antibodies 
against TYROBP, PLCG2, and PTK2B revealed that CD68+ cells were involved in the activation of 
the NK Cell Mediated Cytotoxicity Pathway. PLCG2 in particular had ubiquitous expression not 
restricted to inflammatory cells. Double staining with anti-CD8 as a marker for cytotoxic T cells 
showed that nearly 50% of the lymphatic cells in the AAA wall were CD8+, a number which is 
considerably higher than the 20%–30% described previously [31,32]. Yet, only few CD8+ cells 
expressed TYROBP, PLCG2 or PTK22B suggesting that there is a special subgroup of CD8+ cell 
type. PTK2B and PLCG1 were also expressed in other cell types. Clearly, further studies are needed to 
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characterize the cell types positive for members of the NK pathway. It is of interest to note that the 
activation of the NK Cell Mediated Cytotoxicity Pathway is not restricted to the NK cells in human 
AAA tissue. 
The NK Cell Mediated Cytotoxicity Pathway is known to have features of the innate immune and 
the adaptive immune systems [42] which could explain the expression of the members of the pathway 
in different cell types. In particular, the cytotoxic CD8+ T cell is a close relative of the NK cell [42].  
An increase in cytotoxic cells including NK, NKT and CD8 T-cells and macrophages may contribute 
to AAA pathogenesis by the production of cytotoxic mediators resulting in SMC apoptosis. 
Limitations of the study are the use of surgically removed human aneurysmal aortic tissue which 
shows already end-stage disease, so it is not clear if the NK Cell Mediated Cytotoxicity Pathway is 
already activated in the early stages of the disease. The study was restricted to the aortic tissue. It is, 
therefore, not possible to say if the changes seen constitute a systemic or local reaction. 
4. Experimental Section 
4.1. Human Aortic Tissue Samples 
Aortic wall tissue specimens (six AAA patients; ages ranging from 64 to 72 years, mean age  
68.67 ± 2.56 years) were collected from patients undergoing elective AAA repair operations at the 
Harper University Hospital, Detroit, MI, USA. Non-aneurysmal infrarenal aortic samples were collected 
at autopsies (n = 8; donor ages ranging from 44 to 88 years and mean of 62.25 ± 13.87 years). The same 
autopsy samples have been used in our previous studies and have shown comparable performance in 
mRNA and protein analyses to samples taken from AAA operations [16–20]. Samples were stored in 
phosphate-buffered formalin and embedded in paraffin. Donor information for all samples is listed in 
Table 1. The collection of the human tissues was approved by the Institutional Review Board of 
Wayne State University, Detroit, MI, USA. 
4.2. Microarray-Based Gene Expression Studies 
In our previous study [10], we used two microarray platforms to generate global mRNA expression 
profiles for both aneurysmal (n = 6) and non-aneurysmal (n = 7) human infrarenal abdominal aorta. 
The details on these studies have been described previously, and the microarray data can be obtained at 
the Gene Expression Omnibus (GEO) database (Series #GSE7084)) [43,44]. 
The results revealed 3274 differentially expressed genes between aneurysmal and control aortic 
tissue with False Discovery Rate (FDR) of <0.05. Analysis of biological pathways, including Gene 
Ontology (GO) and KEGG, indicated extreme overrepresentation of immune related categories. The 
enriched categories included the GO category Immune Response (GO: 0006955; FDR = 2.1 × 10−14), 
and the KEGG pathway NK Cell Mediated Cytotoxicity (hsa04650; FDR = 5.9 × 10−6). In the NK Cell 
Mediated Cytotoxicity pathway, 86/127 probed genes were expressed in either AAA or controls 
(AAA: 84; control: 75). Interestingly, 49/86 (57%) of the expressed genes in this pathway were 
significantly differentially expressed between AAA and the controls (Figure 1; see also the Additional 
File 4 in Lenk et al. [10]). There were 43 genes with increased mRNA levels in AAA whereas only  
six genes (MICA, PTPN11, SHC4, PLCG1, PIK3R1, and RAC1) had decreased mRNA levels in AAA 
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(Figure 1). There were also 12 genes with detectable expression in only the AAA tissue (GZMB, 
CD244, FYN, ITGAL, KIR3DL1, KLRK1, NCR3, PRF1, SH2D1B, SH3BP2, TNF, ZAP70), and two 
genes (PIK3R3, NFATC4) expressed only in control aortic tissue (Figure 1). 
Gene symbols available from the National Center for Biotechnology Information (NCBI) [45]  
were used. 
4.3. Immunohistochemical Analysis 
Immunostaining was carried out with formalin-fixed paraffin-embedded tissue sections as described 
previously [46]. The slides were incubated with a primary antibody (Table 2) on an automatic 
immunostainer (Dako Autostainer, Carpinteria, CA, USA). A secondary antibody with peroxidase 
labelled polymer conjugated to either goat anti-mouse or goat anti-rabbit immunoglobulins (Dako, 
Glostrup, Denmark) was used and the signal was detected with substrate chromogen solution (Dako). 
Antibodies for each protein were first tested on tissue known to contain the protein of interest as 
positive controls. Non-specific IgG antibody in lieu of primary antibody served as a negative control 
and gave no staining. Four of the selected antibodies (CD244, SH2D1A; RAC1 and RAF1; Table 2) 
showed no staining even with tissues used as positive controls. In addition, the antibody against LAT 
showed a good specific staining in the positive controls, but no staining in AAA or control aorta. 
Double staining was performed with either an antibody against CD68 (a marker for the 
macrophages/monocytes) or an antibody against CD8A (a marker for cytotoxic T-cells), and the 
antibodies against TYROBP (DAP12), PTK2B (PYK2), or PLCG1. Double staining with antibodies 
against HCST (DAP10) and GMZB was also carried out. The experiments were carried out according 
to the manufacturer’s instructions using kit EnVision™ G/2 Doublestain System, Rabbit/Mouse 
DAB+/Permanent Red (K5261; Dako). 
For evaluation of the stained slides microscope Nikon OPTIPHOT-2 (Tokyo, Japan) and Nikon Digital 
Camera DS-Fi2 were used. The camera software was NIS-Elements V4.10 (Nikon). Images were 
assembled for figures using Image J software (National Institutes of Health, Bethesda, MD, USA) [47]. 
 
Int. J. Mol. Sci. 2015, 16 11207 
 
 
Table 2. Primary antibodies used for immunohistochemical staining of aortic tissue samples. 




PTK2B 2185 PTK2B, PYK2, PKB, 
PTK 
Protein tyrosine kinase 2 β ab55358 ¶ Abcam, Cambridge, MA, USA Rabbit polyclonal 
LAT 27040 LAT, pp36 Linker for activation of T cells ab32070 § Abcam, Cambridge, MA, USA Rabbit monoclonal 
VAV3 10451 VAV3 Vav 3 guanine nucleotide exchange factor ab40889 Abcam, Cambridge, MA, USA Rabbit polyclonal 
RAC2 5880 RAC2, HSPC022,  
p21-Rac2, EN-7 
Ras-related C3 botulinum toxin substrate 2 
(rho family, small GTP binding protein Rac2) 
ab2244 † Abcam, Cambridge, MA, USA Goat polyclonal 
TNF 7124 TNF, TNFA, TNFSF2, 
DIF 
Tumor necrosis factor ab6671 Abcam, Cambridge, MA, USA Rabbit polyclonal 
CD244 51744 CD244, 2B4, NAIL, 
NKR2B4, SLAMF4 
CD244 molecule, natural killer cell  
receptor 2B4 
HPA010628 † Sigma-Aldrich, St. Louis,  
MO, USA 
Rabbit polyclonal 
TYROBP 7305 DAP12, KARAP, 
PLOSL 
TYRO protein tyrosine kinase binding protein sc-20783 ¶ Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Rabbit polyclonal 
HCST 10870 DAP10, KAP10, 
PIK3AP 
Hematopoietic cell signal transducer sc-10531 ¶ Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Goat polyclonal 
SH2D1A 4068 SAP, LYP, DSHP, 
MTCP1, EBVS 
SH2 domain containing 1A sc-8333 † Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Rabbit polyclonal 
VAV1 7409 VAV1, VAV Vav 1 guanine nucleotide exchange factor sc-132 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Rabbit polyclonal 
PLCG1 5335 PLCG1, PLC1, 
NCKAP3, PLC148 
Phospholipase C, gamma 1 sc-7290 Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Mouse 
monoclonal 
PLCG2 5336 PLCG2, FCAS3, 
APLAID 
Phospholipase C, gamma 2 
(phosphatidylinositol-specific) 
sc-5283 ¶ Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Mouse 
monoclonal 
RAC1 5879 RAC1, MIG5,  
TC-25, p21-Rac1 
Ras-related C3 botulinum toxin substrate 1 
(rho family, small GTP binding protein Rac1) 
05-389 † Millipore Corporation, 
Billerica, MA, USA 
Mouse 
monoclonal 
RAF1 5894 RAF1, NS5, CRAF v-raf-1 murine leukemia viral oncogene 
homolog 1 
sc-7267 † Santa Cruz Biotechnology Inc., 
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Table 2. Cont. 




GZMB 3002 GZMB, HLP, CCPI, 
CGL1, SECT, CTLA1, 
CTSGL1 
Granzyme B (granzyme 2, cytotoxic  
T-lymphocyte-associated serine esterase 1) 
sc-1969 ¶ Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA 
Goat polyclonal 
CD8A 925 CD8, MAL, p32, Leu2 CD8a molecule M7103 ¶ Dako, Glostrup, Denmark Mouse monoclonal 
CD68 968 CD68, GP110, 
LAMP4, SCARD1 
CD68 molecule M0876 ¶ Dako, Glostrup, Denmark Mouse monoclonal 
* HGNC approved gene and IDs are available from the HUGO Gene Nomenclature Committee [48] or National Center for Biotechnology Information [45]; † Antibody 
did not stain positive controls and was not used for staining of aortic samples; § Antibody stained positive controls but did not stain aortic tissue samples and results are, 
therefore, not reported here; ¶ Used for double-staining. 
 




The NK Cell Mediated Cytotoxicity Pathway is activated in human AAA tissue based on both 
mRNA expression data and protein analysis using immunostaining. We demonstrated that components 
of the NK pathway and TNFA, GZMB and PRF1, the highly destructive end products, are produced 
not only in NK cells but also in cytotoxic T cells (CD8+) and macrophages (CD68+) in the aneurysmal 
aortic wall. The exact role for inflammation in AAA pathogenesis is still an unanswered question; on 
one hand, there is evidence that inflammation could contribute to AAA progression and on the other 
hand, inflammation could result from an injury in the aortic wall. 
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